# I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

> **NCT05986071** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 57 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** M1774
- **DRUG:** Fulvestrant injection

## Key facts

- **NCT ID:** NCT05986071
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-10-15
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986071, "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05986071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*